Recommendations on deprescribing of bisphosphonates in osteoporosis guidelines: a systematic review

Key summary points Aim To examine whether and how osteoporosis guidelines include recommendations on deprescribing of bisphosphonates. Findings Osteoporosis guidelines include limited guidance on how to make individualized deprescribing decisions based on individual health context. Message More detailed deprescribing guidance may be warranted in osteoporosis guidelines to help prescribers and patients/caregivers make individualized decisions about bisphosphonate therapy for older persons. This should include considerations of treatment goals/preferences, assessment of life expectancy, and weighing benefits/risks of continuation versus deprescribing.